ECG Before Starting Atomoxetine with Family History of Heart Disease
A baseline ECG is recommended before initiating atomoxetine in a patient with a family history of heart disease, particularly if that history includes sudden death, ventricular arrhythmia, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, or long QT syndrome. 1
Clinical Reasoning and Risk Stratification
The 2019 AAP/Pediatrics ADHD guidelines provide clear direction on this issue. While the overall risk of serious cardiovascular events with atomoxetine is extremely low, the guidelines explicitly state that clinicians should obtain personal and family cardiac history, and perform additional evaluation if risk factors are present before starting nonstimulant medications (including atomoxetine). This additional evaluation specifically includes performing an ECG, and possibly referring to a pediatric cardiologist if the ECG is abnormal 1.
What Constitutes High-Risk Family History?
Not all "family history of heart disease" warrants an ECG. The guidelines specify these concerning family history elements:
- Sudden death (particularly in individuals <35 years old, including unexplained motor vehicle accidents, drownings, or SIDS)
- Cardiovascular symptoms in family members
- Wolff-Parkinson-White syndrome
- Hypertrophic cardiomyopathy
- Long QT syndrome
If your patient's family history includes any of these specific conditions, an ECG is warranted 1.
If Family History is Non-Specific
If the "family history of heart disease" refers to common conditions like hypertension, coronary artery disease in elderly relatives, or hyperlipidemia—without the specific high-risk features listed above—then the decision becomes more nuanced. The 2023 Canadian Cardiovascular Society guidelines note that risk stratification and clinical judgment are required, considering the drug, dose, and coexistence of other risk factors 2.
Atomoxetine's Cardiovascular Profile
Atomoxetine can increase heart rate and blood pressure 1. The FDA label warns about serious cardiovascular events and recommends careful cardiac history assessment 3. Recent research from Japan (2024) found an increased risk of arrhythmia during the first 7 days after initial atomoxetine exposure (adjusted IRR 6.22) 4, though a 2013 study found no elevated risk of serious cardiovascular events overall 5.
Research specifically examining atomoxetine's cardiac effects in children found no significant QT prolongation, but did identify subclinical arrhythmias that became more apparent during treatment 6. This supports the value of baseline assessment.
Practical Algorithm
Step 1: Take detailed cardiac history focusing on:
- Personal cardiac symptoms (chest pain, syncope, palpitations, exercise intolerance)
- Family history of sudden death <35 years
- Family history of specific conditions: long QT, WPW, hypertrophic cardiomyopathy, ventricular arrhythmias
Step 2: If ANY of the above are present → Obtain baseline ECG 1
Step 3: If ECG is abnormal → Refer to cardiology before initiating atomoxetine 1
Step 4: If family history is vague/non-specific (e.g., "grandparent had heart attack at age 75") → ECG may be deferred, but measure baseline blood pressure and heart rate 1
Common Pitfalls
- Don't assume all "family history of heart disease" is equal—the specific conditions matter greatly
- Don't skip the detailed cardiac history—this is where you identify the high-risk features that mandate ECG
- Don't forget to monitor vital signs even if you don't obtain an ECG—blood pressure and heart rate should be checked at baseline and periodically during treatment 1
- In adults, be more cautious—sudden deaths, stroke, and MI have been reported in adults on atomoxetine 3, and recent data shows higher arrhythmia risk 4
The FDA label reinforces that patients being considered for atomoxetine should have careful history including assessment for family history of sudden death or ventricular arrhythmia, and should receive further cardiac evaluation if findings suggest cardiac disease 3.